Spots Global Cancer Trial Database for Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Official Title: Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction
Study ID: NCT00113113
Conditions
Interventions
Study Description
Brief Summary: Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Washington University School of Medicine, St. Louis, Missouri, United States
The Center for Cancer Care and Research, St. Louis, Missouri, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
